A Practical Approach to Lipid-Lowering Therapy

Why This Matters

The goal of lipid-lowering therapy is not simply to improve laboratory values. The objective is to reduce the lifetime burden of ApoB-containing lipoproteins, thereby lowering the risk of myocardial infarction, ischemic stroke, peripheral arterial disease, and cardiovascular death. Successful treatment requires addressing the underlying metabolic disorder while selecting therapies that provide the greatest long-term reduction in atherogenic particle exposure.

Start with Lifestyle

Every treatment plan should begin with lifestyle modification.

A heart-healthy lifestyle includes maintaining a healthy body weight, engaging in regular physical activity, avoiding tobacco, obtaining adequate sleep, and controlling blood pressure. For patients with insulin resistance or metabolic syndrome, reducing excess body fat and improving insulin sensitivity are particularly important — the specific dietary and exercise strategies for doing this are covered at length in this book's main chapters. Diet should emphasize minimally processed foods, adequate protein, healthy fats, vegetables, legumes, nuts, and high-fiber foods while minimizing refined carbohydrates, sugar-sweetened beverages, and ultra-processed foods. No medication can fully compensate for poor metabolic health.

Determine the Patient's Risk

Treatment intensity should match cardiovascular risk.

Patients with established atherosclerotic cardiovascular disease, familial hypercholesterolemia, diabetes mellitus with additional risk factors, chronic kidney disease, or markedly elevated ApoB-containing lipoproteins generally require more aggressive therapy than individuals at lower risk. The goal is to intervene early enough to reduce cumulative lifetime exposure to atherogenic particles.

Statins: First-Line Therapy

Statins remain the foundation of pharmacologic lipid management.

By reducing hepatic cholesterol synthesis and increasing LDL receptor expression, they provide the greatest evidence for reducing cardiovascular events. Unless contraindicated or poorly tolerated, statins are the preferred initial medication for most patients requiring lipid-lowering therapy.

Add-On Therapy

When LDL cholesterol or ApoB remains above the desired goal despite maximally tolerated statin therapy, additional medications should be considered.

Ezetimibe is usually the preferred second agent because of its complementary mechanism, excellent safety profile, low cost, and proven clinical benefit. Patients at very high cardiovascular risk may require PCSK9 inhibitors or inclisiran to achieve more substantial reductions in ApoB-containing lipoproteins. Bempedoic acid offers an effective oral alternative for selected patients, particularly those with statin intolerance. ANGPTL3 inhibitors currently have a more specialized role in severe genetic dyslipidemias.

Individualize Treatment

Not every patient requires the same therapeutic approach.

Age, comorbid conditions, medication tolerance, family history, genetic disorders, baseline ApoB, lipoprotein(a), patient preferences, and anticipated lifetime benefit should all influence treatment decisions. Shared decision-making improves adherence and allows therapy to be tailored to each patient's individual risk profile.

Monitor Response

Follow-up is essential.

Repeat lipid measurements confirm therapeutic response, assess adherence, and identify opportunities for further optimization. When available, ApoB provides an excellent measure of treatment effectiveness because it directly reflects the number of circulating atherogenic particles. Lifestyle modification should continue even after treatment goals have been achieved.

Clinical Pearls

• Lifestyle modification remains the foundation of cardiovascular prevention.
• Treatment intensity should reflect overall cardiovascular risk.
• Statins remain first-line pharmacologic therapy.
• Combination therapy is often necessary for high-risk patients.
• ApoB is an excellent marker for monitoring treatment response.

Common Misconceptions

Misconception: Medication eliminates the need for lifestyle modification.

Reality: Lifestyle measures and pharmacologic therapy are complementary and provide the greatest benefit when combined.

Misconception: Every patient should receive the same LDL-lowering strategy.

Reality: Therapy should be individualized according to cardiovascular risk, metabolic health, and patient-specific factors.

Misconception: Once lipid goals are achieved, follow-up is unnecessary.

Reality: Cardiovascular prevention is a lifelong process requiring continued monitoring, reinforcement of healthy habits, and adjustment of therapy when appropriate.

Clinical Bottom Line

Effective lipid management combines healthy lifestyle habits with evidence-based therapies that reduce lifetime exposure to ApoB-containing lipoproteins. Treatment should be individualized, initiated early in patients at increased risk, and monitored over time to achieve durable cardiovascular protection.